GB201010056D0 - Polypeptide vaccine - Google Patents

Polypeptide vaccine

Info

Publication number
GB201010056D0
GB201010056D0 GBGB1010056.8A GB201010056A GB201010056D0 GB 201010056 D0 GB201010056 D0 GB 201010056D0 GB 201010056 A GB201010056 A GB 201010056A GB 201010056 D0 GB201010056 D0 GB 201010056D0
Authority
GB
United Kingdom
Prior art keywords
polypeptide vaccine
vaccine
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1010056.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procure Therapeutics Ltd
Adjuvantix Ltd
Original Assignee
Procure Therapeutics Ltd
Adjuvantix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procure Therapeutics Ltd, Adjuvantix Ltd filed Critical Procure Therapeutics Ltd
Priority to GBGB1010056.8A priority Critical patent/GB201010056D0/en
Publication of GB201010056D0 publication Critical patent/GB201010056D0/en
Priority to PCT/GB2011/051096 priority patent/WO2011158019A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
GBGB1010056.8A 2010-06-16 2010-06-16 Polypeptide vaccine Ceased GB201010056D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1010056.8A GB201010056D0 (en) 2010-06-16 2010-06-16 Polypeptide vaccine
PCT/GB2011/051096 WO2011158019A1 (en) 2010-06-16 2011-06-13 Polypeptide vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1010056.8A GB201010056D0 (en) 2010-06-16 2010-06-16 Polypeptide vaccine

Publications (1)

Publication Number Publication Date
GB201010056D0 true GB201010056D0 (en) 2010-07-21

Family

ID=42471724

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1010056.8A Ceased GB201010056D0 (en) 2010-06-16 2010-06-16 Polypeptide vaccine

Country Status (1)

Country Link
GB (1) GB201010056D0 (en)

Similar Documents

Publication Publication Date Title
HRP20191852T8 (en) Polypeptides
SG11201400432VA (en) Polypeptide vaccine
GB201005005D0 (en) New vaccine
HK1182719A1 (en) Polypeptides
EP2529227A4 (en) Cytomegalovirus-based immunogenic preparations
GB201015132D0 (en) Vaccine composition
GB201012651D0 (en) Peptides
EP2605786A4 (en) Therapeutic peptides
GB201115910D0 (en) Peptides
EP2588135A4 (en) Nanoemulsion vaccines
EP2543387A4 (en) Mucosal vaccine
GB201016494D0 (en) Polypeptide
EP2627674A4 (en) Egfr-based peptides
GB201014965D0 (en) Vaccine
EP2591799A4 (en) Cancer peptide vaccine
GB0917685D0 (en) Antigenic polypeptide
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
EP2757155A4 (en) Novel recombinant bcg vaccine
ZA201302154B (en) Vaccine
EP2714717A4 (en) Phoenixin peptides
GB201010056D0 (en) Polypeptide vaccine
GB201010058D0 (en) Peptide vaccine
GB201001624D0 (en) Peptides for vaccine
GB201012283D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)